04.07.2021, 2314 Zeichen

Marinomed: Marinomed Biotech, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today the topline results for its Phase II clinical trial of Tacrosolv eye drops to treat ocular hay fever symptoms. The results indicate the high potential of tacrolimus being an effective treatment of ocular inflammation exemplified by allergic conjunctivitis and other allergic manifestations. “The higher dose showed significant relief of allergic symptoms in the eyes and also in the nose. The latter is surprising and supports the effectiveness of Tacrolimus also in allergic rhinitis. This topline data strongly supports our hypothesis that a fully solubilized Tacrolimus can be developed as an effective therapy for ocular inflammation including dry eye disease and rhinoconjunctivitis,” commented Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed.
Marinomed Biotech: weekly performance: -1.97%

Andritz: Iternational technology group Andritz has signed an agreement with GE Steam Power to acquire parts of their Air Quality Control System (AQCS) technology, including the technology center in Växjö, Sweden. Closing of the transaction was reached on 1st of July 2021.
Andritz: weekly performance: -2.58%

ams Osram: ams Osram, a global leader in optical solutions, announces the close of the sale of the North America-based Digital Systems business (DS) in the USA, Canada and Mexico to long-time customer and partner Acuity Brands. DS primarily manufactures lighting control systems, electronics and drivers. With a long history of working together spanning decades, the close relationship and mutual understanding of each other’s business is a strong point for the customer base. ams OSRAM and Acuity Brands agreed not to disclose financial details.
AMS: weekly performance: 2.62%

Valneva: Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, indicated it continues ongoing discussions with the European Commission regarding VLA2001, Valneva’s inactivated Covid-19 vaccine candidate.
Valneva: weekly performance: 6.78%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (01/07/2021)

Christian Drastil: Wiener Börse Plausch

Zertifikate Party Österreich 12/24: Diesmal kurze Party, 2025 startet dafür unser Real-Money-Zertifikate-Depot mit 14tägigen Podcasts

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, Warimpex, RHI Magnesita, Immofinanz, Addiko Bank, CA Immo, Mayr-Melnhof, Verbund, ATX, ATX Prime, ATX TR, Wienerberger, Kostad, EVN, Lenzing, Österreichische Post, Strabag, Athos Immobilien, AT&S, Cleen Energy, Marinomed Biotech, RWT AG, SBO, UBM, Agrana, Amag, Flughafen Wien, OMV, Palfinger, Telekom Austria, Uniqa.

---